HomeInsightsStock Comparison

Cipla Ltd vs Zydus Lifesciences Ltd Stock Comparison

Cipla Ltd vs Zydus Lifesciences Ltd Stock Comparison

Last Updated on: May 07, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1509 as of 07 May 10:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 26.2 on March 2024 . This represents a CAGR of 2.37% over 5 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 27344 crore on March 2020 to ₹ 101151 crore on March 2024 . This represents a CAGR of 29.90% over 5 years.
  • The revenue of Cipla Ltd for the Dec '24 is ₹ 7294 crore as compare to the Sep '24 revenue of ₹ 7241 crore. This represent the growth of 0.73% The revenue of Zydus Lifesciences Ltd for the Dec '24 is ₹ 5326 crore as compare to the Sep '24 revenue of ₹ 5305 crore. This represent the growth of 0.4%.
  • The ebitda of Cipla Ltd for the Dec '24 is ₹ 2210 crore as compare to the Sep '24 ebitda of ₹ 2076 crore. This represent the growth of 6.47% The ebitda of Zydus Lifesciences Ltd for the Dec '24 is ₹ 1444 crore as compare to the Sep '24 ebitda of ₹ 1529 crore. This represent the decline of -5.56%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1583 crore over 7 quarters. This represents a CAGR of 30.30% The net profit of Zydus Lifesciences Ltd changed from ₹ 1112 crore to ₹ 1004 crore over 7 quarters. This represents a CAGR of -5.66% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 25.37 % on March 2020 to 8.77 % on March 2024 . This represents a CAGR of -19.14% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
  • The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Cipla Ltd News Hub

News

Cipla's Goa API facility receives VAI status from USFDA

According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection o...

Read more

21 Apr 2025 11:32

News

Cipla allots 23,282 equity shares under ESOS

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

17 Apr 2025 16:12

News

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension

Cipla has received final approval from the United States Food and Drug Administration (USF...

Read more

11 Apr 2025 09:27

News

Cipla jumps on receiving approval from USFDA for protein-bound Paclitaxel

Cipla's formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for...

Read more

11 Apr 2025 10:12

News

Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025. Powered...

Read more

08 Apr 2025 09:40

News

USFDA classifies cGMP inspection of Cipla's Virgonagar facility as VAI

Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the com...

Read more

08 Feb 2025 11:16

Zydus Lifesciences Ltd News Hub

News

Zydus Life gains after USFDA approval for Niacin Extended-Release tablets

The approved medication is indicated for the treatment of patients with primary hyperlipid...

Read more

30 Apr 2025 11:32

News

Zydus receives USFDA approval for Niacin Extended-Release Tablets

Zydus Lifesciences has received final approval from the United States Food and Drug Admini...

Read more

30 Apr 2025 14:52

News

Zydus Life gets 6 observations from USFDA for API plant

The inspection, which ran from 21 to 25 April 2025, culminated with six observations issue...

Read more

26 Apr 2025 11:02

News

Zydus's API unit at Dabhasa, Gujarat concludes USFDA inspection

Zydus Lifesciences announced that the USFDA conducted a surveillance inspection at the gro...

Read more

26 Apr 2025 11:57

News

Zydus Lifesciences to hike its stake in Amplitude Surgical SA

Zydus Lifesciences has signed the share purchase agreement to acquire 75.4% of the share c...

Read more

26 Apr 2025 12:24

News

Zydus Lifesciences Ltd leads losers in 'A' group

Easy Trip Planners Ltd, Dhani Services Ltd, Mahanagar Gas Ltd and Astrazeneca Pharma India...

Read more

16 Apr 2025 15:00

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Zydus Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Cipla Ltd or Zydus Lifesciences Ltd?

Market cap of Cipla Ltd is 122,010 Cr while Market cap of Zydus Lifesciences Ltd is 88,548 Cr

What are the key factors driving the stock performance of Cipla Ltd and Zydus Lifesciences Ltd?

The stock performance of Cipla Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Zydus Lifesciences Ltd?

As of May 7, 2025, the Cipla Ltd stock price is INR ₹1510.7. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹880.0.

How do dividend payouts of Cipla Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Cipla Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions